Related Experiment Videos
Inhibitors in young boys with haemophilia
1Division of Hematology/Oncology, Children's Hospital of Michigan, Detroit 48201, USA.
Insights
Inhibitor antibodies in children with haemophilia pose a significant challenge. Management requires family understanding and involves complex treatments like immune tolerance induction, with varying success rates for factor VIII and factor IX inhibitors.
Area of Science:
- Paediatric Haematology
- Immunology
- Genetics
Background:
- Inhibitor antibody development in children with haemophilia A or B is a major clinical challenge.
- Incidence of inhibitors in severe haemophilia A is high (30-52%), with genetic factors playing a role.
- Understanding inhibitor types (high, low, transient) and their implications is crucial for management.
Purpose of the Study:
- To provide an overview of inhibitor development in childhood haemophilia.
- To discuss the incidence, genetic risk factors, detection, and management of inhibitors.
- To review treatment options for bleeding episodes in children with inhibitors.
Main Methods:
- Literature review and synthesis of current knowledge on haemophilia inhibitors.
- Discussion of diagnostic criteria and classification of inhibitors.
- Analysis of therapeutic strategies, including immune tolerance induction and acute bleeding management.
Main Results:
- Immune tolerance induction is highly effective for factor VIII inhibitors (approx. 85%) but less so for factor IX inhibitors (40-50%).
- Treatment options for high-titre inhibitors include activated prothrombin complex concentrates (APCC), rF VIIa, and porcine factor VIII.
- Factor IX inhibitors, though less common (2-3%), are associated with a high risk of anaphylaxis (approx. 50%).
Conclusions:
- Effective management of haemophilia inhibitors requires comprehensive understanding and tailored treatment approaches.
- Patient and family education is paramount for successful treatment adherence and outcomes.
- Further research into optimizing inhibitor management and prevention strategies is warranted.
Abstract:
The development of an inhibitor antibody to factor VIII (or factor IX) in a child with haemophilia presents a major challenge to the paediatric haematologist. This article provides an overview of the incidence of inhibitor development in early childhood (30-52% in boys with severe haemophilia A), genetic risk factors, detection, high titre, low titre and transient inhibitors, and management. Treatment of patients with inhibitors is time-consuming and expensive. One should make every attempt to ensure that the boy's family has an understanding of inhibitors, treatment options, and just what is being recommended for their child and what this involves. Immune tolerance induction is successful in approximately 85% of boys with factor VIII inhibitors, but in only 40-50% of those with factor IX inhibitors. For treatment of bleeding episodes in children with high-titre (> or = 5 Bethesda Units) inhibitors, therapeutic options include activated prothrombin complex concentrates (APCC), rF VIIa, and (for factor VIII inhibitors) porcine factor VIII. The advantages and disadvantages of each are discussed. Although factor IX inhibitors are far less common (occurring in 2-3% of boys with haemophilia B), approximately 50% are accompanied by the occurrence of anaphylaxis or severe allergic reactions to any factor IX-containing product.